BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lew D, Yoon SM, Yan X, Robbins L, Haritunians T, Liu Z, Li D, McGovern DP. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients. World J Gastroenterol 2017; 23(40): 7265-7273 [PMID: 29142473 DOI: 10.3748/wjg.v23.i40.7265]
URL: https://www.wjgnet.com/1007-9327/full/v23/i40/7265.htm
Number Citing Articles
1
Dalin Li, Talin Haritunians, Carol Landers, Alka A Potdar, Shaohong Yang, Hailiang Huang, L Philip Schumm, Mark Daly, Stephan R Targan, Dermot P B McGovern. Late-Onset Crohn’s Disease Is A Subgroup Distinct in Genetic and Behavioral Risk Factors With UC-Like CharacteristicsInflammatory Bowel Diseases 2018; 24(11): 2413 doi: 10.1093/ibd/izy148
2
Maya Zvuloni, Manar Matar, Rachel Levi, Dror S. Shouval, Raanan Shamir, Amit Assa. High anti‐TNFα Concentrations Are Not Associated With More Adverse Events in Pediatric Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition 2021; 73(6): 717 doi: 10.1097/MPG.0000000000003240
3
Cong Dai, Yi-nuo Wang, Wen-ning Tian, Yu-Hong Huang, Min Jiang. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysisInternational Immunopharmacology 2022; 112: 109269 doi: 10.1016/j.intimp.2022.109269
4
Ruize Liu, Dalin Li, Talin Haritunians, Yunfeng Ruan, Mark J. Daly, Hailiang Huang, Dermot P.B. McGovern. Profiling the inflammatory bowel diseases using genetics, serum biomarkers, and smoking informationiScience 2023; 26(10): 108053 doi: 10.1016/j.isci.2023.108053